Rahul Gosain: Hepatocellular Cancer – 2nd line treatment and when to switch
Rahul Gosain, Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, shared a post on LinkedIn:
“GI Series: Hepatocellular Cancer 2/4: 2L Treatment and when to switch with Lorenza Rimassa and Professor Dr. Arndt Vogel.
- IO, TKIs, support oncology in 2L.
- AEs/Management.
Also on the Oncology Brothers podcast.
Video attached to the post.”
Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.
Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.
More posts featuring Rahul Gosain.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023